Benefits
Rapid rise in blood ketones
MCTs — particularly C8 caprylic acid — are converted to ketone bodies (beta-hydroxybutyrate, acetoacetate) in the liver within 30–90 minutes of consumption, even without dietary carbohydrate restriction. Ketones are a usable fuel for brain and muscle, and blood beta-hydroxybutyrate does rise measurably after a dose. Whether that translates into feeling more alert or energetic is much less certain. In a placebo-controlled crossover in 80 healthy older adults, 30 g/day raised blood ketones without changing cognition or memory-related brain activity. The trials that have measured how people feel are few and weak: a 12-week manufacturer-run study in sedentary adults aged 60 to 74 reported better self-rated physical and general health, but MCT was given alongside a walking program so the two cannot be separated, and in people with multiple sclerosis an MCT-based ketogenic diet raised blood ketones while doing less for fatigue and quality of life than a comparison diet.
Weight management and satiety
Replacing long-chain fats with MCT produces a small but repeatable weight difference. Pooled across 11 randomized trials the difference was 0.69 kg of body weight, 0.89 kg of body fat and 1.78 cm of waist circumference; a second meta-analysis of 13 trials in 749 adults found 0.51 kg and 1.46 cm. Bueno and colleagues rated the overall quality of that evidence low to moderate, and Mumme and Stonehouse reported that commercial bias was detected and that independent confirmation is still needed. Food intake does fall: pooled across 17 studies in 291 people, MCT modestly reduced how much was eaten at a later meal. The hormone explanation does not hold up. Across those same studies there was little evidence of any effect on subjective appetite ratings or on circulating gut hormones, and in the one crossover that measured them directly, peptide YY rose but glucagon-like peptide-1 did not, and the authors concluded the drop in food intake was not mediated by GLP-1, PYY or insulin.
Ketones reach the brain; the cognition trials are mixed
The brain does take up ketones, and imaging in older adults confirms MCT raises brain ketone uptake several fold. The cognitive results are mixed and the trials are small. Pooled across 10 studies in people with mild cognitive impairment or Alzheimer's disease, MCT improved general cognition (standardised mean difference 0.64, 95% CI 0.05 to 1.24) but not memory, language or attention specifically. In people without dementia the picture is inconsistent: of six randomized trials reviewed, four reported better memory, chiefly working memory, but the two largest placebo-controlled trials in healthy older adults, one in 80 people over 14 days and one in 63 people over 3 months, found no cognitive change at all. The disease trials do not carry over either. A 90-day manufacturer-run trial of the caprylic-triglyceride medical food AC-1202 in 152 people with Alzheimer's found a 1.9-point ADAS-Cog difference at day 45 that persisted to day 90 only in APOE4 non-carriers, and the follow-up trial built around exactly that finding, in 413 patients over 26 weeks, missed by 0.76 ADAS-Cog11 points (p = 0.25) with every secondary measure null. A 6-month trial in 52 people with mild cognitive impairment reported cognitive gains, but its primary endpoint was brain ketone metabolism and the cognitive changes were reported against each group's own baseline rather than against placebo. AC-1202 is a medical food used under medical supervision, and medical foods are not FDA-approved.
Ketogenic diet support
MCT oil enables more liberal carbohydrate intake while maintaining ketosis, making the ketogenic diet more sustainable and flexible. Endurance performance is a separate question, and the trials have not been kind. Twelve trained runners taking 60 g/day for two weeks ran no longer to exhaustion than on corn oil, with no difference in VO2max or in blood ketones. In eight ultra-endurance cyclists, sprint and time-trial times were slower with MCT than with carbohydrate, and half the riders had gastrointestinal symptoms.
Antimicrobial activity, in the laboratory only
Caprylic acid (C8) and capric acid (C10) inhibit Candida albicans and some gram-positive bacteria in culture. Almost all of that work is laboratory work. The only human trial is a 12-infant randomized pilot in preterm babies, where MCT supplementation reduced Candida in the stool during the week it was given and fungal burden rose again once it stopped. No trial has tested MCT oil or caprylic acid in adults for candida overgrowth or small intestinal bacterial overgrowth, and neither is a condition to self-treat with a supplement.
Mechanism of action
Portal vein absorption bypassing lymphatic transport
Unlike long-chain fatty acids (LCFAs) that require incorporation into chylomicrons for lymphatic transport, MCTs are absorbed directly into the portal vein as free fatty acids. This direct hepatic delivery means MCTs are available for energy production within 30 minutes of consumption — explaining the rapid energy effect and higher thermogenic impact.
Hepatic ketogenesis via mitochondrial beta-oxidation
MCTs enter liver mitochondria without requiring carnitine transport (unlike LCFAs), enabling immediate beta-oxidation to acetyl-CoA. When acetyl-CoA production exceeds TCA cycle capacity (as with high MCT intake or carbohydrate restriction), it is diverted to ketogenesis — producing beta-hydroxybutyrate and acetoacetate as exportable fuel for the brain, heart, and muscle.
Thermogenic effect and uncoupling protein activation
MCT feeding raises uncoupling protein expression in brown adipose tissue in rodents; the same measurement has not been made in people. What has been measured in people is energy expenditure, and the effect is small and fades: in 24 overweight men, expenditure ran 0.04 kcal/min higher on MCT than on olive oil at day 2 and was no longer significant by day 28. MCT oil has a higher thermic effect than LCT-based fats — contributing to the observed greater weight loss in MCT vs. olive oil comparisons.
Clinical trials
Randomized controlled trial comparing MCT oil (18-24 g/day) with olive oil inside a supervised weight-loss program: 49 overweight adults aged 19 to 50 randomized, 31 completed, 16 weeks. (St-Onge MP, Bosarge A. Am J Clin Nutr. 2008 Mar;87(3):621-6. PMID 18326600)
49 overweight adults aged 19 to 50 randomized; 31 completed. 16-week intervention.
Endpoint body weight was 1.67 kg lower on MCT oil than on olive oil (P = 0.013). Loss of total fat mass (P = 0.071) and trunk fat mass (P = 0.10) only trended in MCT's favour and did not reach significance, although endpoint trunk fat, total fat and intra-abdominal fat were each lower on MCT. Two later meta-analyses put the pooled MCT-versus-long-chain weight difference at 0.69 kg across 11 trials and 0.51 kg across 13 trials in 749 adults. An adjunct to calorie restriction, not a substitute for it.
Randomized, double-blind, placebo-controlled parallel-group trial of caprylidene (AC-1202, ~20 g/day caprylic triglyceride) vs placebo in 152 adults with mild-to-moderate Alzheimer's disease for 90 days. Designed, funded and authored by Accera, Inc. (now Cerecin), which makes the product. (Henderson ST, Vogel JL, Barr LJ, et al. Nutr Metab (Lond). 2009;6:31. PMID 19664276)
152 mild-moderate AD patients. 90-day intervention.
Blood beta-hydroxybutyrate rose 2 hours after dosing. On the cognitive endpoint, the whole randomized group differed from placebo by 1.9 ADAS-Cog points at day 45 but not at day 90; only the APOE4 non-carriers (n = 55) still differed at day 90, by 3.36 points. That subgroup finding was then tested head-on and did not replicate: a 26-week trial of the same caprylic triglyceride in 413 patients with mild-to-moderate Alzheimer's, with the primary analysis prespecified in APOE4 non-carriers, found a difference of 0.76 ADAS-Cog11 points that was not statistically significant (p = 0.25), and the secondary measures were null as well. AC-1202 is Axona, a medical food used under medical supervision, not a retail MCT oil, and nothing here supports buying MCT oil to affect memory.